Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026

Published: 2026-05-13 10:20:23 ET FATE

Published on 05/13/2026 at 10:20 am EDT

Fate Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 31.21 million compared to USD 37.62 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.32 a year ago.

Diluted loss per share from continuing operations was USD 0.26 compared to USD 0.32 a year ago.